Drug Design and Delivery for Intracellular Bacteria: Emerging Paradigms

Intracellular bacteria exploit host cell niches, such as lysosomes, phagosomes, cytosol, entire cells, and even erythrocytes, to evade immune clearance and escape conventional antibiotics. These environments pose numerous therapeutic challenges, including crossing host cell membranes, navigating endosomal trafficking, tolerating acidic and redox conditions, bypassing efflux mechanisms, and countering phenotypic tolerance. Although recent advancements in nanotechnology-such as carriers, prodrugs, and host-directed therapies-offer promising solutions, current strategies remain narrowly focused on "getting the drug inside the cell", leaving therapeutic agents vulnerable to off-site targeting, degradation, and functional failure. This review introduces a next-generation approach for intracellular antibacterial therapy, incorporating subcellular targeting, dual-function delivery systems, innovative biomimetic carriers, precise intracellular pharmacokinetics/pharmacodynamics (PK/PD) assessment, and artificial intelligence-assisted drug design. Highlighting frameworks for multimodal regimens targeting intracellular bacteria, we advocate a transition from solely facilitating cellular entry to achieving precise spatiotemporal regulation of drug activity within infected host cells. This paradigm informs the development of therapeutics designed to persist within the intracellular bacterial niche, minimizing relapse and reducing the emergence of antimicrobial resistance.